Assessment of anti-PD-(L)1 for patients with coexisting malignant tumor and tuberculosis classified by active, latent, and obsolete stage

BACKGROUND: It is not a rare clinical scenario to have patients presenting with coexisting malignant tumor and tuberculosis. Whether it is feasible to conduct programmed death-(ligand) 1 [PD-(L)1] inhibitors to these patients, especially those with active tuberculosis treated with concurrent anti-tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Shan, Ye, Mei-Feng, Cai, Xiao-Ting, Bai, Xue, Huang, Zhi-Hao, Ma, Si-Cong, Zou, Jian-Jun, Wen, Yu-Xiang, Wu, Li-Juan, Guo, Xue-Jun, Zhang, Xian-Lan, Cen, Wen-Chang, Su, Duo-Hua, Huang, Hui-Yi, Dong, Zhong-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686368/
https://www.ncbi.nlm.nih.gov/pubmed/34923987
http://dx.doi.org/10.1186/s12916-021-02194-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686368/
https://www.ncbi.nlm.nih.gov/pubmed/34923987
http://dx.doi.org/10.1186/s12916-021-02194-z

Ejemplares similares